Cervical Disk Arthroplasty Versus Anterior Cervical Decompression and Fusion for the Treatment of 2-Level Cervical Spondylopathy: A Systematic Review and Meta-analysis.

Abstract

Systematic review and meta-analysis. To assess the safety and efficacy of cervical disk arthroplasty (CDA) compared with anterior cervical decompression and fusion (ACDF) for the treatment of 2-level cervical spondylopathy. CDA has emerged as a potential alternative to ACDF in patients with cervical disk degeneration. But there are no published systematic reviews and meta-analyses comparing CDA with ACDF for the treatment of 2-level cervical spondylopathy. The Pubmed, Embase, Web of science, Scopus, and Cochrane library databases were searched comparing CDA to ACDF in patients with 2-level cervical spondylopathy. Outcome measures were neck disability index, visual analog scale (VAS) of arm and neck pain, range of movement (ROM) at C2-C7, functional segment unit ROM, ROM at the operated level, and incidence of radiologic changes at adjacent levels approximately 2 years after surgery, as well as operating time and incidence of surgery-related complications. Mean difference (MD), odds ratios (OR), and their corresponding 95% confidence intervals (95% CIs) were calculated. Six studies involving 646 patients were included. There were no significant differences in neck disability index (MD, -1.53; 95% CI -3.80 to 0.73), VAS neck pain (MD, -0.19; 95% CI -0.71 to 0.33), and VAS arm pain (MD, -0.23; 95% CI -0.61 to 0.16) between 2-level CDA and 2-level ACDF cases. ROM at C2-C7 (MD, 15.82; 95% CI, 10.66-20.99), functional segment unit ROM (MD, 8.58; 95% CI, 7.93-9.23), and ROM at the operated level (MD, 9.54; 95% CI, 7.73-11.35) were greater, but the incidence of radiologic changes at adjacent levels (OR, 0.29; 95% CI, 0.13-0.67) were lower, in 2-level CDA cases. In 2-level CDA cases, the operating time was longer (MD, 57.41; 95% CI, 24.67-90.14), but surgery-related complications rates (OR, 0.47; 95% CI, 0.30-0.74) was lower. CDA may be a safe and effective alternative to ACDF for the treatment of 2-level cervical degenerative disease. Level II.